Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors

Inclusion Criteria:

* Subjects must have a histologically or cytologically confirmed advanced solid tumor at screening.
* Male or female equal or greater than 18 years of age.
* All female subjects of childbearing potential must each have a negative serum pregnancy test result before initiating study treatment.
* An Eastern Cooperative Oncology Group (ECOG) performance status equal or less than 2
* Adequate bone marrow, liver, and renal function, defined as:

  * Platelet count equal or greater than 75 x 10(9)/L
  * Hemoglobin (Hb) equal or greater than 9.0 g/dL
  * Absolute neutrophil count (ANC) equal or greater than 1.5 x 10(9)/L
  * Total bilirubin equal or less than 1.5 x upper limit of normal (ULN)
  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal or less than 3 x ULN (equal or less than 5 x ULN for subjects with liver metastases)
  * Serum creatinine equal or less than 1.5 x ULN

Exclusion Criteria:

* History of cardiac disease: Active coronary artery disease (CAD), defined as myocardial infarction (MI), unstable angina, coronary bypass graft (CABG), or stenting within 6 months prior to study entry (an MI that occurred \> 6 months prior to study entry is permitted)
* Evidence of uncontrolled bradycardia or other cardiac arrhythmia defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0, or uncontrolled hypertension
* Active, clinically serious infection(s) defined as equal or greater than Grade 2 according to NCI CTCAE, version 4.0.
* Known metastatic brain or meningeal tumors, unless the subject is \> 3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of first dose of study drug.
* Prior therapy with mesenchymal-epithelial transition factor (c-MET) inhibitors, including ARQ 197.